CVS to Replace AbbVie’s Blockbuster Humira With Cheaper Rivals

Bloomberg01-04

The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.Starting April 1, CVS Health Corp. will no longer offer AbbVie ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2400807677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-04 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2400807677","market":"us","top_or_hot":-1,"title":"CVS to Replace AbbVie’s Blockbuster Humira With Cheaper Rivals","media":"Bloomberg","content":"<div>\n<p>The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.Starting April 1, CVS Health Corp. will no longer offer AbbVie ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvs-replace-abbvie-blockbuster-humira-224859453.html\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS to Replace AbbVie’s Blockbuster Humira With Cheaper Rivals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS to Replace AbbVie’s Blockbuster Humira With Cheaper Rivals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-04 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cvs-replace-abbvie-blockbuster-humira-224859453.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.Starting April 1, CVS Health Corp. will no longer offer AbbVie ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvs-replace-abbvie-blockbuster-humira-224859453.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1496350171.SGD","symbol_name":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/cvs-replace-abbvie-blockbuster-humira-224859453.html","article_id":"2400807677","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2400807677","pubTimestamp":1704331704,"columns":[],"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.Starting April 1, CVS Health Corp. will no longer offer AbbVie I","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","CVS":"西维斯健康","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4566":"资本集团","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4196":"保健护理服务","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4559":"巴菲特持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4550":"红杉资本持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","ABBV":"艾伯维公司","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"CVS用更便宜的竞争对手取代艾伯维的重磅炸弹Humira","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"CVS":1},"content_text":"The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.Starting April 1, CVS Health Corp. will no longer offer AbbVie Inc.’s Humira to most of the millions of patients in its commercial prescription plans. Instead, they’ll be directed to cheaper copycats of the anti-inflammatory drug that became available last year. CVS’s Caremark unit is the first major pharmacy benefit manager to announce such a shift. It’s a blow for AbbVie, which managed to keep Humira on PBMs’ lists of covered drugs even when plans added lower-cost versions alongside it. Humira sales topped $21 billion in 2022, the biggest drug outside of Covid vaccines. With the rise of copycats, known as biosimilars, analysts project sales of Humira to drop to about $9 billion this year.AbbVie shares fell as much as 4% in extended trading after US markets closed. A company representative said changes to formularies were expected and that Humira remains widely available.CVS’s drug plans began adding some of the first new versions of the drug from Sandoz Group AG and other rivals last year. At the same time, CVS joined with Sandoz to co-produce a version of a Humira biosimilar through a new business unit called Cordavis.Patients who are being switched from Humira to biosimilars will get 60 days’ notice and assistance with the change, CVS said. The substitution is expected to save CVS’s clients more than 50% compared with 2022 prices, before biosimilar competition.Humira will still be available for employers or health plans that want to keep access to it, CVS said. The changes don’t affect patients on Medicare or Medicaid plans.CVS’s Cordavis unit will also start selling a version of Humira with AbbVie in the second quarter, though it won’t be preferred on CVS’s commercial drug plans.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2400807677"}